Regeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
Get Alerts REGN Hot Sheet
Revenue Growth %: +2.2%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.92, $0.15 worse than the analyst estimate of $3.07. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.3 billion.
2017 Financial Guidance(3)
The Company's updated full year 2017 financial guidance consists of the following components:
EYLEA U.S. net product sales | Single digit percentage growth over 2016 (reaffirmed) | |||
Sanofi reimbursement of Regeneron commercialization-related expenses | $385 million - $425 million (previously $400 million - $450 million) | |||
Non-GAAP unreimbursed R&D(2)(4) | $950 million - $1.025 billion (reaffirmed) | |||
Non-GAAP SG&A(2)(4) | $1.140 billion - $1.200 billion (previously $1.175 billion - $1.250 billion) | |||
Effective tax rate | 32% - 38% (reaffirmed) | |||
Capital expenditures | $300 million - $350 million (previously $375 million - $450 million) |
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Park National Corp. (PRK) Tops Q1 EPS by 36c
- Acme United (ACU) Misses Q1 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!